OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format.

挪威奥斯陆，2024年6月11日（环球通讯社）--Nykode Therapeutics ASA（OSE:NYKD）是一家致力于发现和开发新型免疫疗法的临床阶段生物制药公司，今天在波士顿举行的癌症免疫疗法会议上宣布了其mRNA平台的更新。该公司强调了其创新的APC靶向新抗原疫苗的显着优势，该疫苗以mRNA脂质纳米颗粒（LNP）形式递送。

This latest study demonstrated that the APC-targeted vaccine consistently achieved a broader and more robust immune response across doses compared to an untargeted neoantigen vaccine. It also provided superior tumor control and resulted in dramatically improved survival rates in a mouse model of colorectal cancer.

这项最新研究表明，与非靶向新抗原疫苗相比，靶向APC的疫苗在不同剂量下始终获得更广泛和更强大的免疫应答。它还提供了优越的肿瘤控制，并大大提高了结直肠癌小鼠模型的存活率。

Chief Scientific Officer, Agnete Fredriksen, commented on the findings, 'Our latest data not only emphasize the effectiveness of the APC-targeted approach but also confirm our platform's potential across modalities to significantly advance the treatment landscape for cancer. The strong data demonstrating Nykode’s potential to improve mRNA vaccines underscore our commitment to leading the way in next-generation immunotherapies.' Nykode presented a poster detailing these findings at the meeting, with further information available on the Nykode website: https://nykode.com/research-and-development/scientific-papers-and-presentations.

首席科学官阿格妮特·弗雷德里克森（AgneteFredriksen）对这些发现发表了评论，“我们的最新数据不仅强调了针对APC的方法的有效性，而且证实了我们的平台在各种方式上的潜力，可以显着改善癌症的治疗前景。有力的数据表明，Nykode有潜力改进mRNA疫苗，这突显了我们致力于在下一代免疫疗法中领先。”Nykode在会议上展示了一张海报，详细介绍了这些发现，Nykode网站上提供了更多信息：https://nykode.com/research-and-development/scientific-papers-and-presentations.

Nykode remains dedicated to pushing the boundaries of cancer treatment and improving patient outcomes through innovative research and development. About Nykode Therapeutics Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases.

Nykode仍然致力于推动癌症治疗的界限，并通过创新的研究和开发来改善患者的预后。关于Nykode Therapeutics Nykode Therapeutics是一家临床阶段的生物制药公司，致力于发现和开发新型免疫疗法，重点治疗癌症和自身免疫性疾病。

Nykode’s modular vaccine te.

Nykode的模块化疫苗te。